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Abstract It is widely accepted that the standard ﬁrst-line
treatment for most endocrine inactive pituitary macroade-
nomas (EIA) is surgery, usually via a transsphenoidal
approach. What is less clear is what approach to take when
these tumors recur, especially when this recurrence
involves areas which are difﬁcult to surgically remove
tumor from, such as the suprasellar region or cavernous
sinuses. We present long term follow-up for a series of 81
patients who underwent repeat surgery for recurrent non-
secreting pituitary adenomas. We analyzed data collected
from all adult patients undergoing their second microsur-
gical transsphenoidal resection of a histologically proven
endocrine-inactive pituitary adenoma at the University of
California at San Francisco between January 1970 and
March 2001. Data for these patients were collected by
review of medical records, mail, and/or telephone inter-
views. Visual function, anterior pituitary function, and
tumor control rates were analyzed for the series. Records
were available for a total of 81 recurrent EIA patients. The
median time between their initial and repeat operations was
4.1 years. The mean tumor size was 2.2 ± 0.2 cm. A total
of 35/81 patients had greater than 5 years of follow-up. A
total of 24/81 patients had greater than 10 years of follow-
up. Over one half of these patients presented with visual
disturbance, and we found that 39% of these patients
experienced improved vision with a second surgery. More
importantly, no one with normal vision suffered any
appreciable decline in vision. Approximately, 35% of
patients with pre-operative anterior pituitary dysfunction
recovered function after surgery in our series; and no
patient’s function worsened. A total of 4/52 (8%) patients
with greater than 2 years of post-op follow-up experienced
a clinically meaningful tumor recurrence requiring addi-
tional treatment. Our data suggest that when performed by
experienced transsphenoidal surgeons, durable tumor con-
trol can be obtained in these frequently locally aggressive
tumors with acceptable rates of post-operative morbidity.
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Introduction
While many pituitary adenomas are hormonally active and
cause systemic symptoms by secreting hormones in an
uncontrolled fashion, a large fraction of pituitary adenomas
cause morbidity through local mass effect compressing the
neighboring normal adenohypophysis and the optic appa-
ratus [4, 14]. It is widely accepted that the standard ﬁrst-
line treatment for most endocrine inactive pituitary mac-
roadenomas (EIA) is transsphenoidal surgery [2, 4, 7, 10,
14]. Modern transsphenoidal surgery generally can achieve
excellent tumor control rates, with a minimal amount of
discomfort and morbidity [2, 7, 10, 11, 18].
What is less clear is what approach to take when these
tumors recur, especially when this recurrence involves
areas which are difﬁcult to surgically remove tumor from,
such as the suprasellar region or cavernous sinuses [16].
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DOI 10.1007/s11102-010-0221-zGiven that in most cases these recurrent tumors are usually
not hormonally active, there is less of a clear indication for
repeat attempts at curative or cytoreductive surgery. In
many institutions, recurrent tumors are treated with repeat
surgical resection, however, the evolution of less invasive
treatments, such as radiosurgery and conformal radiother-
apy [9, 12], raises the possibility of avoiding a repeat
operation, especially in cases where surgical cure is difﬁ-
cult or unlikely. These options become more appealing in
light of the difﬁculties of repeat transsphenoidal surgery
[8]: the bony landmarks useful in maintaining a midline
trajectory are frequently distorted and destroyed from the
previous surgery, and there is frequently exuberant muco-
sal overgrowth and scar tissue in the surgical ﬁeld, making
orientation more difﬁcult [17, 8]. Further, given that these
tumors are not hormonally active, one could make the
argument that many patients with recurrent tumors should
not be treated at all, especially if the tumor is not surgically
curable.
Our ability to determine the best treatment for these
patients is most limited by the lack of long term follow-up
data for patients undergoing repeat surgery at time of
recurrence [2]. Much more has been written about the
management of residual or recurrent hormonally active
pituitary adenomas where the appropriate management
approach is largely dictated by laboratory data [1, 5, 6, 8].
The lack of deﬁnitive data regarding the risk and efﬁcacy
proﬁles of various approaches for treating recurrent EIA’s
is especially problematic given that these tumors are gen-
erally slow growing, and evaluation of the true efﬁcacy of
any treatment must take into account the possibility of very
late second recurrences [2]. We present long term follow-
up for a series of 81 patients who underwent repeat surgery
for recurrent non-secreting pituitary adenomas. Our aim
was to delineate the safety and efﬁcacy proﬁle so that it can
be compared to other treatment modalities.
Methods
Patient population
We analyzed data collected from 81 adult patients under-
going their second microsurgical transsphenoidal resection
of a histologically proven endocrine-inactive pituitary
adenoma at the University of California at San Francisco
by two surgeons (C.W. and S.K.) between January 1970
and March 2001. All patients had undergone a previous
technically adequate transsphenoidal resection at least
2 years prior to the operation in question (meaning the
operations were not performed in the early post-operative
period for technical mistakes leaving large residual tumors
[13], but rather represented true recurrences). No patient in
this series had previously undergone radiation therapy prior
to the second surgery. Early repeat operations for technical
failures, and patients with clinical or radiographic evidence
of pituitary apoplexy were excluded from this analysis.
Data collection and analysis
Data for these patients were collected retrospectively at a
number of time points between 1994 and 2004 by review
of medical records, mail, and/or telephone interviews.
Hospital and clinic records were reviewed to extract data
pertaining to patient age, dates of surgery, pre-operative
symptoms, pre and post-operative endocrine and visual
ﬁeld tests, intra-operative ﬁndings, post-operative compli-
cations, radiation therapy, and clinical evidence of recur-
rence. Pre and post-operative T1 weighted post-gadolinium
MRI images were evaluated to determine tumor size, tumor
characteristics, such as suprasellar and cavernous sinus
invasion, and the extent of tumor resection.
Visual function was assessed in all patients using formal
visual acuity testing and formal perimeter ﬁeld testing. The
timing of this analysis post-operatively was variable, but
was general performed at least 3 months post-operatively
if the patient was not complaining of visual decline.
Improvement in visual function was deﬁned as [30%
reduction in visual ﬁeld deﬁcit and/or meaningful
improvement in visual acuity on post-operative examina-
tion. Worsening in visual function was deﬁned as any new
visual ﬁeld cut, or any signiﬁcant decline in visual acuity
post-operatively. Visual function was deﬁned as ‘‘unchan-
ged’’ if no change or minor change occurred on both tests.
Anterior pituitary function was tested in all patients pre-
and post-operatively. We decided to focus our analysis on
Gonadal, Thyroid, Hypothalamic–pituitary–adrenal (HPA)
axis function. Pre-operative anterior pituitary dysfunction
was deﬁned as endocrinologic evidence of secondary
endocrine dysfunction (hypothyroidism with low TSH,
hypocortisolemia with low ACTH, or secondary gonadal
failure), or the need for hormone replacement therapy.
Because no patients without pre-operative anterior pituitary
dysfunction in this cohort developed it post-op, analysis
was limited to patients with pre-operative dysfunction.
Post-operative improvement in anterior pituitary function
was deﬁned as the normalization of one or more previously
abnormal anterior pituitary functions off replacement
therapies at last follow-up, without new dysfunction of
another hormone system. Post-operative worsening in
anterior pituitary function was deﬁned as a newly abnormal
anterior pituitary function, or new need for long term
hormone replacement. Patients were not considered to have
worsening if they transiently required hormone replace-
ment for several months following surgery (i.e. short term
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123cortisol replacement), but eventually had normal function
off replacement therapy at last follow-up.
Post-operative tumor recurrence/progression was
deﬁned as unequivocal radiographic evidence of new
tumor or clinically signiﬁcant tumor growth in a known
residual nest of tumor.
Statistical analysis
All between group comparisons of binary variables were
performed using Fisher’s exact test. Survival analysis of
tumor recurrence was performed using the Kaplan–Meier
method with between group survival comparisons being
made using the Log-rank test. All continuous variables are
presented as mean ± SE.
Results
Patient characteristics
Records were available for a total of 81 recurrent EIA
patients. The median time between the initial and repeat
operations was 4.1 years. The median age was 50.4 years
(range 20–92 years). The mean tumor size was
2.2 ± 0.2 cm. The median length of follow-up was
3.62 years(range6 monthsto21 years)(Table 1).Atotalof
35/81 patients had greater than 5 years of follow-up. A total
of 24/81 patients had greater than 10 years of follow-up.
The most common presenting symptom for these
patients was visual dysfunction (49 of 81 patients, 60%).
A total of 36% (29/81 patients) of patients had anterior
hypopituitarism, and 33% (27/81 patients) presented with
headache. A total of 19 patients (23%) had asymptomatic
radiographic recurrence (Table 1).
A total of 51/81 of these tumors demonstrated supra-
sellar extension, 15/81 had cavernous sinus invasion, and
9/81 had an infrasellar/intrasphenoidal component. A total
of 9 tumors had some intrasellar cystic component. A total
of 19/81 tumors were purely intrasellar.
Factors inﬂuencing the frequency of clinical and
radiographic gross total resection
The treating surgeon felt a gross total resection (GTR) had
been achieved in 32/81 cases, with the other 49 cases
receiving subtotal resections (STR). We found that the
surgeon’s intra-operative impression of extent of resection
did not correlate well with post-operative imaging ﬁndings,
with discordant ﬁndings being found in 39% of the 60
cases for which adequate post-operative imaging was
available for review. A total of 39/60 of these patients had
no evidence of residual disease on post-operative imaging,
while 21/60 patients demonstrated residual tumor. Sur-
geons were signiﬁcantly more likely to underestimate the
extent of resection (i.e. to feel that tumor was left behind
when it was not visible on the scan) compared to imaging
ﬁndings than to overestimate them (P\0.001) (Table 2a).
A statistical trend towards more frequent subtotal
resections occurred in patients with infrasellar/intrasphe-
noidal tumor extension (P = 0.09). While suprasellar
extension and cavernous sinus invasion were more fre-
quently observed in patients receiving subjective subtotal
Table 1 Pre-operative clinical characteristics for the 81 patients in
this series
Patient demographics
Age 50.4 years 20–92 years
Follow-up 3.62 years 6mo–21 years
Size 2.2 ± 0.2 cm
# of Patients (%)
Deﬁcit
Visual ﬁeld deﬁcits 49/81 60
Hypopituitarism 29/81 36
Headache 27/81 33
Incidental ﬁnding 19/81 24
Imaging characteristics
Suprasellar extension 51/81 63
Infrasellar/intrasphenoidal
extension
9/81 11
Cavernous sinus invasion 15/81 19
Intratumoral cyst 9/81 11
Purely intrasellar 19/81 23
Table 2 (A) Rates of discordance between intraoperative impression
and imaging assessment of extent of resection. Note that discordance
for GTR patients means that the post-operative MRI demonstrated
residual disease. For STR patients, this means no residual disease was
seen on post-operative MRI. (B) Rates of gross total resection for
patients with and without various types of extrasellar tumor resection
GTR STR
(A)
Discordance 4 20
Concordance 19 18
(B)
Imaging characteristics
Suprasellar extension 20 31
Infrasellar/intrasphenoidal extension 1 8
Cavernous sinus invasion 4 11
Intratumoral cyst 3 6
Purely intrasellar 9 10
Note that no signiﬁcant difference exists between groups for any
category (*-GTR Gross total resection, STR Subtotal resection)
Pituitary (2010) 13:223–229 225
123total resections, neither of increased the statistical likeli-
hood of subtotal resections compared to purely intrasellar
tumors (Table 2b).
Patients with cavernous sinus extension demonstrated a
statistical trend towards increased rates of having radio-
graphic residual disease seen on post-operative scans
compared to patients with purely intrasellar tumors
(P = 0.07). Suprasellar extension, infrasellar/intrasphe-
noidal extension, and intratumoral cysts demonstrated no
signiﬁcant increase in rates of radiographic residual com-
pared to purely intrasellar tumors.
Visual outcomes following repeat transsphenoidal
resection
Post-operatively, 95% of all patients had the same or
improved visual function compared to pre-op. All four
patients with worsened vision, had initial visual dysfunc-
tion pre-op, thus no patient with normal pre-op vision
suffered visual decline post-operatively. Further, none of
these patients went onto have known visual loss during the
follow-up period. When analysis was limited to the 49
patients with pre-operative visual compromise, we found
that the rate of meaningful partial or complete visual
recovery was 39%. A total of 4/49 patients had worse
vision post-op. Sub-set analysis found that extent of
resection did not have any effect on visual outcomes in
these patients (Table 3).
Endocrine outcomes following repeat transsphenoidal
resection
As stated in the methods, no patient without hypopituita-
rism pre-op developed it post-op. Further, no patient had
worse endocrine function post-op than they had pre-op. Of
patients with pre-existing endocrine dysfunction, 10/29
patients (35%) experienced improvement in anterior pitu-
itary function compared to pre-op, while 19/29 maintained
the same endocrine function.
Gross total resection did not lead to statistically
improved endocrine outcomes at last follow-up, regardless
of whether it was deﬁned on clinical or radiographic
grounds (Table 4).
The effect of gross total resection on recurrence
following repeat resection
A total of 52 patients had greater than 2 years of post-op
follow-up. A total of 4/52 (8%) of these patients experi-
enced a clinically meaningful tumor recurrence requiring
additional treatment. These recurrences were discovered at
2.0, 5.1, 5.7, and 7.7 years following the repeat operation.
A total of 3 of these 4 patients had suprasellar extension on
their pre-operative scan. None of these patients had cav-
ernous sinus invasion. The overall 2, 5, and 10 years
recurrence rates were 1/52 (1.9%), 3/35 (8.6%), and 4/24
(17%), respectively. When analysis was limited to only
patients followed by MRI, 2, 5, and 10 years recurrence
rates were 1/43 (2.3%), 3/27 (11%), and 4/20 (20%),
respectively.
Two of four patients with recurrence had intra-operative
ﬁndings consistent with gross total resection, while 2/4
received a subtotal resection. Figure 1a, b demonstrate that
there was no difference in tumor control rates between
patients receiving gross total resection and subtotal resec-
tion, even when analysis was limited to patients followed
with MRI alone.
The rationale for XRT was largely based on the treating
clinician’s preference. In the 2, 5, and 10 years tumor
control cohorts described above, early post-operative XRT
was administered to 23/52 (43%), 8/35 (23%), and 8/24
(33%) patients, respectively. Kaplan–Meier analysis
(Fig. 1c) comparing surgery to surgery ? XRT demon-
strated no difference in tumor control rates between the
groups. We also performed subgroup analyses limited to
only patients who received subtotal resections, and to those
who were followed with MRI imaging, and in both cases
found no difference between the groups with regard to
tumor control rates.
Table 3 Post-operative visual outcomes at latest follow-up in the 49
patients who presented with pre-operative visual dysfunction
GTR STR Overall (%)
Improved 7 12 19 39
Same 10 16 26 53
Worse 2 2 4 8
Note that no signiﬁcant difference exists between groups for any
category (*-GTR Gross total resection, STR Subtotal resection)
Table 4 Post-operative endocrinologic outcomes at latest follow-up
in the 29 patients who presented with pre-operative anterior pituitary
dysfunction. Note that no signiﬁcant difference exists between groups
for any category. Table (A) compares impact of extent of resection
based on subjective intraoperative impression while the data in Table
(B) assess extent of resection using MRI imaging
Endocrine function GTR STR
Better 7 3
Same 9 10
Worse 0 0
Endocrine function GTR Residual
Better 3 4
Same 10 6
Worse 0 0
(*-GTR Gross total resection, STR Subtotal resection)
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123The effect of external beam radiotherapy following
repeat transsphenoidal resection
A total of 35/81 patients in this cohort underwent external
beam radiation therapy following their repeat surgery. A
total of ﬁve of these patients had received subjective gross
total resection, and 15 patients had no evidence of disease
on their post-operative MRI. Treatment protocols were
largely consistent (38–50 Gy. over 25 fractions in all
patients). Patient outcomes are summarized in Table 5.
Visual outcomes were marginally improved in patients
receiving radiation therapy though this difference was not
signiﬁcantly different. Of note, 3 of 4 patients whose vision
worsened post-op did not receive radiation therapy.
Endocrine outcomes did not differ signiﬁcantly between
patients receiving radiotherapy and those that did not. Of
note, no patient receiving radiation had worse post-opera-
tive endocrine function than their pre-op function.
Morbidity and mortality following repeat
transsphenoidal resection
A total of 18/81 (22%) patients experienced at least one
non-endocrine, non-visual complication related to their
surgery. These are summarized in Table 6. There was one
Fig. 1 Kaplan–Meier analyses
comparing tumor control rates
in patients undergoing a GTR
vs. STR, b GTR vs. STR limited
to recurrences monitored during
MRI era, c surgery versus
surgery ? XRT
(*-GTR = Gross total
resection, STR = Subtotal
resection)
Table 5 Post-operative visual and endocrinologic outcomes at latest
follow-up in the 35 patients who received post-operative external
beam radiation therapy
Visual function XRT None
Better 12 12
Same 22 31
Worse 1 3
Endocrine function XRT None
Better 3 8
Same 7 9
Worse 0 0
Note that no signiﬁcant difference exists between groups for any
category
Table 6 Rates of post-operative non-visual, non-endocrinologic
complications for patients in this series
Complication # of Patients Rate (%)
Overall 18 22
DI 4 4.9
Permanent DI 1 1.2
Hyponatremia 3 3.7
Sinusitis 5 6.2
Spinal headache 5 6.2
Meningitis 2 2.5
Post-operative hematoma 2 2.5
Death 1 1.2
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123death within the early post-operative period from medical
complications stemming from a post-operative hematoma
requiring repeat evacuation. Permanent posterior pituitary
dysfunction was rare, as permanent diabetes insipidus
occurred in 1/81 patients. Only 2/81 patients experienced
meningitis due to CSF leak post-operatively, and 5/81
patients had clinically signiﬁcant post-op sinusitis. There
were no other episodes of transient CSF rhinorrhea. No
new cranial neuropathy was noted in any patient post-op.
Discussion
In this study, we present long term data from a large cohort
of patients undergoing repeat transsphenoidal surgery for
recurrent non-secreting pituitary macroadenomas. Our data
suggest that when performed by experienced transsphe-
noidal surgeons, durable tumor control can be obtained in
these frequently locally aggressive tumors with acceptable
rates of post-operative morbidity. While it is tempting to
refer these patients to radiosurgery in an attempt to save
them a second operation [12], it should be noted that these
tumors can change their hormonal and biologic phenotype
at the time of recurrence [15]. Given the good results we
have seen with repeat surgery, we feel monotherapy with
radiosurgery should be undertaken only in select cases
when after endocrinologic work-up, it is certain that the
tumor has not become a hormone secreting tumor.
Probably the most interesting ﬁnding of our analysis is
the relatively low rate of clinically important tumor
recurrence/progression (8% at 5 years following the second
operation), even though a large number of these patients
(35%) had at least some residual tumor left on imaging. A
number of these patients with residual disease have been
followed well past 10 years, and in a few cases 20 years,
without evidence of tumor growth requiring treatment.
Also, interesting was the observation that none of the 24
patients in this cohort who made it to 10 years of follow-up
without clinically signiﬁcant tumor growth/regrowth, went
onto have a subsequent recurrence. While the number of
recurrences in this group was too low to make any deﬁn-
itive conclusions regarding recurrences rates, radiographic
gross total resection did not seem to have a protective
effect, or at least subtotal resection did not seem to pre-
dispose to certain recurrence in this group.
Over one half of these patients presented with visual
disturbance, and in this cohort we found that 39% of these
patients experienced improved vision with a second sur-
gery. More importantly, no one with normal vision (in
whom the indication for surgery is less certain), suffered
any appreciable decline in vision. Interestingly, leaving a
small amount of residual did not appear to make a differ-
ence in long term outcome, as these tumors infrequently
recur, and when they do, they seldom make vision worse.
While 8% of patients with pre-op visual compromise had
post-operative visual worsening, these cases were evenly
divided between subtotal and gross total resection, sug-
gesting that the visual decline was not necessarily due to
overaggressive attempts to obtain a gross total resection.
Approximately, 35% of patients with pre-operative
anterior pituitary dysfunction recovered function after
surgery in our series, and no patient’s function worsened.
This is important to note, as at repeat transsphenoidal
surgery due to scar tissue it can be more difﬁcult to discern
clear planes between tumor and normal gland than at the
initial surgery, and as such, it wouldn’t be unreasonable to
hypothesize that repeat surgery would have a higher rate of
hypopituitarism. This does not seem to be the case whether
a gross total or subtotal resection is performed, or even if
the patient receives external beam radiotherapy. Why this
rate seems to be lower than published rates for initial
operation is not entirely clear, but perhaps a pseudocapsule
of scar tissue around the gland protects the normal tissue at
repeat surgery.
While these data and that reported by others demonstrate
repeat transsphenoidal surgery can generally be performed
with good results and a low amount of major morbidity [1],
the single mortality in this series highlights the potential
serious risk of repeat surgery, as typical landmarks and
tissue planes helpful in the initial surgery, are not present at
repeat surgery, increasing the risk of intrasellar and intra-
cranial bleeding and the attendant complications resulting
from these problems. Our complication rates for repeat
surgery are slightly higher than those observed for very
experienced transsphenoidal surgeons performing initial
surgery [3]. The surgeon and patient must be aware of these
risks when weighing the beneﬁts and risks of a repeat entry
into the sella.
Rational therapy for recurrent EIA’s involves assess-
ment and application of the cost-risk–beneﬁt balance
between treatment, continued observation, and radiation
therapy. At time of recurrence, the histologic diagnosis of
these tumors has been established, and the primary man-
agement goal of these tumors is the prevention of endo-
crine and visual morbidity related to tumor growth. Given
the lack of hormonal hypersecretion for these tumors, the
cost-risk–beneﬁt balance largely centers around the issue
of tumor control, and necessity of treatment for obtaining
tumor control. While our data suggest that repeat surgery is
a reasonable and safe option for achieving tumor control, it
is certainly not the least invasive or least costly method for
achieving this goal. While it is possible that recurrence of
tumor implies a persistently growing tumor phenotype,
more data regarding the natural history of untreated
recurrent EIA’s are needed to determine what fraction, if
any, of these tumors plateau in growth, and what fraction
228 Pituitary (2010) 13:223–229
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history of recurrent EIA’s is necessary to determine the
relative feasibility of observation of recurrent EIA’s, and
to determine the indications for repeat transsphenoidal
surgery.
In short, we provide long term follow-up data demon-
strating that repeat transsphenoidal surgery is a reasonable
and effective therapy for large recurrences of endocrine
inactive pituitary macroadenomas, which can be performed
with good visual and endocrine outcomes, and a low rate of
3rd recurrence, even when followed out over a decade.
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